Emily Carter analyzes regulatory, policy, and governance issues influencing biotechnology and medical innovation. Her work examines how regulatory decisions, legal frameworks, and public policy shape research, commercialization, and patient access. At The Catalyst Brief, Emily brings a systems-level perspective, linking policy developments with scientific and market realities.
144 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Biopharmaceutical IndustryThe approval covers Pasatru, also known as garetosmab and REGN2477 during development, to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP. The launch changes the structure of a market that had only one approved drug, with Mirum Pharmaceuticals also approaching an FDA decision on zilurgisertib by Sept. 26.
Emily CarterAug 21, 2026
Medical TechnologyFocal therapy aims to destroy MRI-visible prostate lesions without removing or irradiating the whole gland, offering a less aggressive option than surgery or radiation for some patients with localized disease. A recent 10-year U.K. study reported 0.1% prostate cancer mortality, but the American Urological Association still says the approach should be limited to studies and prospective registries.
Emily CarterAug 21, 2026
Regulatory & PolicySTAT said trust has become central to its mission after the Covid-19 pandemic and amid what it called a defining crisis in science. The publication hired Nicholas Florko to lead a new reporting beat focused on misinformation, how it spreads, and what can be done to counter it.
Emily CarterAug 21, 2026Muscle dysmorphia is currently categorized under obsessive-compulsive and related disorders, even though it often involves extreme dieting and other eating-related behaviors. Nagata argues that moving it into the eating disorder framework would better match how patients present in practice, while critics say the existing classification is already accurate and can be paired with an eating disorder diagnosis when appropriate.
Emily CarterAug 20, 2026
Healthcare InvestmentQuarterly biopharma venture capital deployment topped $10 billion last month for the third time since early 2022, and VC-backed exits reached a collective $34.4 billion. PitchBook argues that the lagged effect of that capital should begin showing up in pharma services demand in late 2026 or early 2027.
Emily CarterAug 18, 2026
Healthcare InvestmentTwo business signals emerged from STAT’s reporting on health care finance. UnitedHealth disclosed an IRS investigation that could raise its taxable income for 2017 through 2020 and potentially later years, while a separate report showed physician practice management deals are on track to run at about half last year’s level as state oversight expands.
Emily CarterAug 17, 2026
Healthcare InvestmentItaly ranks tenth globally and fourth in Europe for overall research output, according to the Nature Index, but investors argue the more important shift is that financing and company-building infrastructure are becoming more dependable. The signal for healthcare investors is less about a sudden breakout than about whether Italy can keep more value onshore as startups scale.
Emily CarterAug 17, 2026
Regulatory & PolicyThe 2024 rule changes were meant to do more than alter paperwork for opioid treatment programs; they were meant to change how clinics and state overseers think about control, access and patient autonomy. What is emerging now is a mixed picture in which operational change appears real at many sites, but proof of a full cultural shift remains incomplete.
Emily CarterAug 14, 2026
Healthcare InvestmentAvalyn Pharma said it raised $345 million in an upsized IPO and began trading on Nasdaq April 30, while Generate Biomedicines raised $400 million earlier this year. The reporting shows that the public offering window may be more available in 2026, but only for teams that have already done the shareholder, governance, and execution work before the filing process starts.
Emily CarterAug 13, 2026The executive order signed Monday calls for fewer vaccines to be recommended for all children in the U.S. and for a shift away from combination products, starting with measles, mumps, and rubella. WHO officials said the policy is based on a disproven autism claim and warned that breaking up vaccines would increase the number of injections and the complexity of the schedule.
Emily CarterAug 13, 2026
Healthcare InvestmentAs part of the 2027/2028 federal budget, the Austrian government has pledged backing for a dedicated capital growth fund that could translate into up to half a billion euros for Austrian companies. The fund is not biotech-only, but industry advocates are pushing for life sciences to capture a large share as Austria tries to convert research strength into larger domestic companies.
Emily CarterAug 12, 2026
Regulatory & PolicyThe Department of Health and Human Services on Monday outlined a proposed shift in the treatment of substances deemed “generally recognized as safe,” or GRAS. The change stops short of pre-market approval, but it would force notice to the Food and Drug Administration for new ingredients and create a public database of existing GRAS uses, narrowing what agency officials described as a decades-old information gap.
Emily CarterAug 10, 2026